BIXTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:39):

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans...

Stats
本日の出来高	88 741.00
平均出来高	105 229
時価総額	17.36M
EPS	$-0.00734 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.00
ATR14	$0.00400 (3.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Milanova Radka	Buy	70 423	common
2024-04-19	Conaway Dale H	Buy	70 423	common
2024-04-19	Hoberman Alan M	Buy	70 423	common
2024-04-19	Milanova Radka	Sell	0	common
2024-03-27	Utter Anders	Buy	266 955	common

INSIDER POWER
89.92
Last 84 transactions
Buy: 33 376 843 \| Sell: 11 429 961

Bioxytran, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Bioxytran, Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$-3 644.00 (0.00 %)
EPS:	$-0.0214

FY	2022
収益:	$0
総利益:	$-3 644.00 (0.00 %)
EPS:	$-0.0214

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0420

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0271

Financial Reports:

No articles found.

Bioxytran, Inc.

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.